This edition of Manufactur3D’s ‘Rapid 3D Printing News‘ series brings you 3D printing news about partnerships between Evonik and Evolve Additive Solutions and between Jabil and Renault F1 Team and Organovo’s multi-party collaboration to develop bioprinted tissue treatments.
Evonik signs agreement with Evolve Additive Solutions to Develop & Qualify its Thermoplastic Materials for STEP 3D Printing Technology
Earlier this week Evonik and Evolve Additive Solutions, Inc. signed a joint agreement to develop and qualify Evonik’s thermoplastic materials to be used in Evolve Additive’s STEP 3D Printing Technology.
The immediate effort will be focussed on qualifying polyamide 12, PEBA, transparent polyamide, and polymer of the polyamide 6 series. In the coming future the collaboration will continue to develop newer 3D printing material choices and include materials that are commonly used in traditionally manufactured products.
Speaking on the joint agreement, Steve Chillscyzn, CEO of Evolve Additive Solutions said, “STEP has been developed for volume manufacturing so offering the widest range of thermoplastic materials to our customers is a critical element for production. The joint development agreement with Evonik allows us to broaden the spectrum of STEP materials to include materials currently accepted by OEMs from additive manufacturing, but more importantly to debut a whole new set of materials opening up more applications that can take advantage of everything additive manufacturing offers.”
According to Thomas Grosse-Puppendahl, the Head of the Additive Manufacturing Innovation Growth Field at Evonik added, “Evolve’s entirely new technology approach will allow us to expand the range of applications of our high-performance materials, which are produced through a unique production process. With more than 20 years of experience in 3D printing, we will also develop a wider range of customised material formulations to unlock the full potential of the STEP technology.”
Jabil signs agreement with Renault F1 Team to speed the Development and Delivery of 3D Printed Racecar Parts
Last week Jabil, a manufacturing solutions provider, announced the signing of an agreement with Renault F1 team to speed the development and delivery of 3D printed racecar parts for the Renault R.S.19. The car is competing in the 2019 Formula One World Championship. Through the Jabil Additive Manufacturing Network, Renault F1 Team will gain fast and efficient access to top-quality parts.
Commenting on the agreement, Jabil’s VP of digital manufacturing John Dulchinos said, “We’re excited to be part of Renault F1 Team’s strategy to improve performance with additive manufacturing. Our ability to consolidate a global supply chain and scale qualified processes as needed will enable the production of chassis and on-car components in record time.”
Excited at the collaboration, Antoine Magnan, Head of Partnerships, Renault Sport Racing explains, “Every single aspect of what we do is geared towards excellence. We look forward to taking advantage of Jabil’s growing ecosystem of certified materials, processes and machines to boost parts availability and overall productivity.”
Renault has been an early adopter of additive manufacturing technology in its product development cycle and manufacturing. The Renault F1 Team continually seeks opportunities to produce racecar parts quickly and economically while reducing vehicle weight and without compromising part strength or integrity and it believes additive manufacturing provides the perfect solution.
Organovo announced multi-party collaboration to Develop Stem Cell-Based Bioprinted Tissue Treatments for Renal Disease
Organovo Holdings, Inc., a biotechnology company pioneering the development of 3D bioprinted tissues, announced a multi-party collaboration to expand the use and adoption of 3D bioprinted stem cell-based therapeutic tissues to applications aimed at treating end-stage renal disease.
The collaboration, generously funded by Stem Cells Australia and CSL Limited, will use Organovo’s Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise.
The parties involved in the collaboration are Organovo, Professor Melissa Little at the Murdoch Children’s Research Institute (“MCRI”), The Royal Children’s Hospital, Melbourne, Australia and Ton Rabelink at Universiteit Leiden (“LUMC”), Leiden, Netherlands.
Excited about the collaboration, Taylor J. Crouch, CEO, Organovo exclaimed, “Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues. This collaboration is another important step in this direction. With the devoted support of Stem Cells Australia and CSL Limited, leading researchers are able to leverage Organovo’s powerful bioprinting technology platform to achieve significant breakthroughs.”
Equally excited is Professor Melissa Little the Theme Director of Cell Biology at Murdoch Children’s Research Institute said, “We have continued to advance and refine our proprietary approach for modeling human kidney tissue from stem cells. By using Organovo’s bioprinter, we can create a stem-cell based therapeutic tissue that may serve as an important step in treating kidney disease. We are grateful to Organovo, Stem Cells Australia and CSL Limited for their ongoing support of our work in regenerative medicine.”
About Manufactur3D Magazine: Manufactur3D is an online magazine on 3D Printing. Visit our Global News page for more updates on 3D Printing Technology News. To stay up-to-date about the latest happenings in the 3D printing world, like us on Facebook or follow us on LinkedIn.
